Henoch–Schönlein purpura (HSP), currently designated as IgA vasculitis in international classifications, is a leukocytoclastic small-vessel vasculitis mediated by IgA immune complex deposition [1]. It predominantly affects children and usually follows an acute and self-limited course [2].
In adults, HSP is less common but characterized by a more heterogeneous clinical presentation and, most importantly, by more frequent and severe renal involvement, which represents the main determinant of long-term prognosis [2–4]. Chronic recurrent forms beginning in adolescence and evolving for many years before the onset of visceral involvement are rarely described in the literature [5].
We report a case illustrating this particular disease course and questioning the truly benign nature of long-standing recurrent purpura.
CASE REPORT
A 30-year-old woman with no significant past medical history reported intermittent episodes of cutaneous purpura involving the lower limbs since the age of 18 years. These episodes were self-limiting, mildly extensive, non-painful, and had never led to medical consultation.
The disease course remained quiescent for several years, with infrequent and paucisymptomatic recurrences. In 2022, the patient reported a flare of purpuric lesions occurring shortly after the first dose of a COVID-19 vaccine, without associated systemic symptoms. From May–June 2025, in a context of major psycho-emotional stress, purpuric lesions became more frequent, more extensive, and painful, involving the lower and upper limbs, face, and perineal area, and were associated with inflammatory polyarthralgia affecting both large and small joints.
The patient also reported moderate colicky abdominal pain, without gastrointestinal bleeding or bowel habit changes. There was no fever, weight loss, or general condition impairment. Physical examination revealed palpable purpura predominantly affecting the lower limbs, without skin necrosis (Figure 1). Blood pressure was 110/60 mmHg. No respiratory, neurological, or ENT manifestations were noted.
FIGURE LEGEND
Figure 1. Palpable purpura involving the lower limbs, predominantly affecting the ankles and feet, consistent with cutaneous manifestations of IgA vasculitis. The lesions are non-necrotic and distributed in a dependent pattern, typical of Henoch–Schönlein purpura.
Laboratory investigations showed no significant inflammatory syndrome. Renal function was preserved. However, biologically significant renal involvement was detected, with proteinuria of 1.7 g/24 h, microscopic hematuria, and aseptic leukocyturia, without nephrotic syndrome.
Immunological testing revealed negative antinuclear antibodies and ANCA, normal complement levels, and absence of cryoglobulinemia. Viral serologies were negative.
A skin biopsy performed during an active phase demonstrated leukocytoclastic vasculitis of small vessels. Direct immunofluorescence revealed IgA and C3 deposits within vessel walls, confirming the diagnosis of Henoch–Schönlein purpura.
The indication for renal biopsy was discussed within a multidisciplinary team primarily for prognostic purposes; however, the procedure was ultimately declined by the patient after detailed information was provided. Systemic oral corticosteroid therapy combined with angiotensin-converting enzyme inhibitor therapy was subsequently initiated.
The clinical course under treatment was favorable, with progressive regression of purpuric lesions and polyarthralgia within weeks. Proteinuria decreased significantly during follow-up, without deterioration of renal function. Corticosteroids were gradually tapered according to standard protocols, with no clinical or biological relapse at the time of last follow-up.
Henoch–Schönlein purpura is a systemic small-vessel vasculitis characterized by IgA1-dominant immune deposits within vessel walls [6]. Although classically described as an acute disease of childhood, adult-onset HSP displays distinct clinical and prognostic features, particularly a higher risk of renal involvement [2–4].
The major clinical relevance of this case lies in the discrepancy between a long-standing, apparently benign cutaneous course and the delayed occurrence of biologically significant renal involvement. This observation illustrates that, in adults, HSP may follow an insidious course for many years before visceral manifestations become evident, independently of the apparent severity of initial skin involvement.
In adults, renal involvement is reported in approximately half of cases and represents the main prognostic factor [3,4]. It may range from isolated urinary abnormalities to progressive chronic kidney disease [4,7]. In our patient, significant proteinuria associated with microscopic hematuria contrasted with preserved renal function and absence of systemic inflammatory markers.
This dissociation highlights the limitations of relying solely on inflammatory markers when assessing disease severity. Indeed, inflammatory parameters are inconsistently elevated in adult HSP and do not reliably reflect renal disease activity [3,6]. Therefore, the absence of systemic inflammation should not lead to underestimation of potential renal severity, and persistent urinary abnormalities must be regarded as warning signs.
The indication for renal biopsy in adult IgA vasculitis remains a matter of debate and is not systematic, as emphasized in recent expert reviews and consensus statements [7–9]. Its primary role is prognostic rather than diagnostic, particularly when the diagnosis is supported by typical clinical features and cutaneous histology demonstrating IgA deposition. Renal biopsy is generally recommended in cases of rapidly progressive renal impairment, nephrotic syndrome, or significant proteinuria associated with declining renal function, as histological findings may directly influence therapeutic decisions [7–9].
In contrast, in patients with preserved renal function, absence of nephrotic syndrome, and moderate isolated proteinuria, renal biopsy may reasonably be discussed or deferred, as it is unlikely to alter initial management [8,9]. Current guidelines and expert reviews support the initiation of nephroprotective therapy and, in selected cases, systemic corticosteroids even in the absence of renal biopsy when renal involvement is biologically significant and the diagnosis of IgA vasculitis is well established [7–10].
In the present case, although renal biopsy was considered within a multidisciplinary framework for prognostic assessment, its absence did not compromise diagnostic accuracy or therapeutic management. The favorable clinical and biological response observed under corticosteroid therapy further supports the appropriateness of the chosen strategy, while highlighting renal biopsy as a valuable prognostic tool rather than a mandatory diagnostic step in this context.
The favorable response to systemic corticosteroid therapy, with improvement of both clinical manifestations and proteinuria, further supports the relevance of early therapeutic intervention. This suggests that timely identification of renal involvement, even in the absence of overt clinical severity, may improve short- and mid-term outcomes.
Finally, this case emphasizes that recurrent purpura of long duration should always be considered a potentially systemic disease, warranting prolonged and systematic monitoring, particularly with regard to renal involvement.
A recurrent purpura since adolescence should not be systematically considered benign. Chronic forms of Henoch–Schönlein purpura may evolve insidiously and be complicated by delayed renal involvement in young adults. Long-term clinical and urinary monitoring is essential to allow early detection of visceral involvement and timely therapeutic intervention, potentially improving prognosis.
Key points
The authors would like to thank the patient for her cooperation.
CONSENT
Written informed consent was obtained from the patient for publication of this case report.
The authors declare no conflicts of interest.
[1] Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
[2] Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch–Schönlein purpura in adults. N Engl J Med. 2002;347(16):1279–1285.
[3] Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N, et al. IgA vasculitis in adults: clinical features and outcomes. Medicine (Baltimore). 2017;96(28):e7289.
[4] Ho?evar A, Rotar Z, Ostrovršnik J, Jur?i? V, Vizjak A, Dolenc Volj? M, et al. Prognostic factors in adult IgA vasculitis. Rheumatology (Oxford). 2014;53(2):331–337.
[5] García-Porrúa C, Calviño MC, Llorca J, Couselo JM, González-Gay MA. Henoch–Schönlein purpura in adults and children: different clinical expression and prognosis. Medicine (Baltimore). 2001;80(5):279–290.
[6] Floege J, Amann K. Primary glomerulonephritides. Nat Rev Nephrol. 2016;12(11):655–668.
[7] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.
[8] Pillebout E. IgA vasculitis in adults: diagnosis and management. Autoimmun Rev. 2019;18(2):102–108.
[9] Ronkainen J, Nuutinen M, Koskimies O. Renal involvement in IgA vasculitis: indications for kidney biopsy and treatment. Clin J Am Soc Nephrol. 2021;16(4):601–609.
[10] Pillebout E, Sunderkötter C. IgA vasculitis in adults: current perspectives. Nephrol Dial Transplant. 2020;35(12):2093–2101.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications